Robin von Rotz

685 total citations · 1 hit paper
17 papers, 427 citations indexed

About

Robin von Rotz is a scholar working on Cellular and Molecular Neuroscience, Clinical Psychology and Organic Chemistry. According to data from OpenAlex, Robin von Rotz has authored 17 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cellular and Molecular Neuroscience, 10 papers in Clinical Psychology and 5 papers in Organic Chemistry. Recurrent topics in Robin von Rotz's work include Psychedelics and Drug Studies (10 papers), Neurotransmitter Receptor Influence on Behavior (8 papers) and Neuroscience and Neuropharmacology Research (5 papers). Robin von Rotz is often cited by papers focused on Psychedelics and Drug Studies (10 papers), Neurotransmitter Receptor Influence on Behavior (8 papers) and Neuroscience and Neuropharmacology Research (5 papers). Robin von Rotz collaborates with scholars based in Switzerland, Italy and Germany. Robin von Rotz's co-authors include Erich Seifritz, Franz X. Vollenweider, Katrin H. Preller, Johannes Jungwirth, Peter J.C.M. Nowak, Nathalie M. Rieser, Lutz Jäncke, Dario Dornbierer, Boris B. Quednow and Oliver G. Bosch and has published in prestigious journals such as NeuroImage, Neuropsychopharmacology and Molecular Psychiatry.

In The Last Decade

Robin von Rotz

16 papers receiving 416 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial

2022 215 citations Robin von Rotz, Johannes Jungwirth et al. EClinicalMedicine profile →

Peers

Countries citing papers authored by Robin von Rotz

Since Specialization

Citations

This map shows the geographic impact of Robin von Rotz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin von Rotz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin von Rotz more than expected).

Fields of papers citing papers by Robin von Rotz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin von Rotz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin von Rotz. The network helps show where Robin von Rotz may publish in the future.

Co-authorship network of co-authors of Robin von Rotz

This figure shows the co-authorship network connecting the top 25 collaborators of Robin von Rotz. A scholar is included among the top collaborators of Robin von Rotz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin von Rotz. Robin von Rotz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study 2025 ·Biomedicine & Pharmacotherapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Helena Aicher, (unknown), Philippe Müller, (unknown), Maxim Puchkov, Angela Äbelö, Erich Seifritz, Boris B. Quednow, Robin von Rotz, Milan Scheidegger, Dario Dornbierer	3
2	Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects 2025 ·Biomedicine & Pharmacotherapy ·Angela Äbelö, (unknown), Robin von Rotz, Dario Dornbierer, (unknown), Michael C. Ashton, Milan Scheidegger	0
3	Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial 2025 ·EClinicalMedicine ·Nathalie M. Rieser, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Robin von Rotz, Carlos Nordt, (unknown), (unknown), (unknown), (unknown), Erich Seifritz, Franz X. Vollenweider, Marcus Herdener, Katrin H. Preller	7
4	Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects 2024 ·Frontiers in Psychiatry ·Helena Aicher, Michael J. Mueller, Dario Dornbierer, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Robin von Rotz, Birgit Kleim, Milan Scheidegger	18
5	Psilocybin increases emotional empathy in patients with major depression 2024 ·Molecular Psychiatry ·Johannes Jungwirth, Robin von Rotz, Isabel Dziobek, Franz X. Vollenweider, Katrin H. Preller	5
6	TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology 2023 ·iScience ·(unknown), (unknown), Simone Sarasso, Silvia Casarotto, Robin von Rotz, Andrea Casanova, Erich Seifritz, Katrin H. Preller, Giulio Tononi, Franz X. Vollenweider	20
7	Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine 2023 ·Frontiers in Pharmacology ·Dario Dornbierer, (unknown), (unknown), Helena Aicher, Michael J. Mueller, (unknown), Michael Kometer, (unknown), Robin von Rotz, Maxim Puchkov, Thomas Kræmer, Hans‐Peter Landolt, Erich Seifritz, Milan Scheidegger	15
8	Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial breakdown → 2022 ·EClinicalMedicine ·Robin von Rotz, (unknown), Johannes Jungwirth, (unknown), Nathalie M. Rieser, (unknown), Erich Seifritz, (unknown), Peter J.C.M. Nowak, Lutz Jäncke, Katrin H. Preller, Franz X. Vollenweider	215
9	Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring 2019 ·European Neuropsychopharmacology ·Dario Dornbierer, Michael Kometer, Robin von Rotz, Erich Studerus, Jürg Gertsch, M. Salomé Gachet, Franz X. Vollenweider, Erich Seifritz, Oliver G. Bosch, Boris B. Quednow	2
10	Gamma-hydroxybutyrate increases brain resting-state functional connectivity of the salience network and dorsal nexus in humans 2018 ·NeuroImage ·Oliver G. Bosch, Fabrizio Esposito, Dario Dornbierer, (unknown), Robin von Rotz, Michael Kometer, Philipp Stäempfli, Boris B. Quednow, Erich Seifritz	10
11	Prohedonic properties of gamma‐hydroxybutyrate are associated with changes in limbic resting‐state functional connectivity 2018 ·Human Psychopharmacology Clinical and Experimental ·Oliver G. Bosch, Fabrizio Esposito, Dario Dornbierer, Robin von Rotz, Rainer Kraehenmann, Philipp Stäempfli, Boris B. Quednow, Erich Seifritz	8
12	Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy male volunteers 2017 ·Psychopharmacology ·Robin von Rotz, Michael Kometer, Dario Dornbierer, Jürg Gertsch, M. Salomé Gachet, Franz X. Vollenweider, Erich Seifritz, Oliver G. Bosch, Boris B. Quednow	14
13	Gamma-Hydroxybutyrate Increases Resting-State Limbic Perfusion and Body and Emotion Awareness in Humans 2017 ·Neuropsychopharmacology ·Oliver G. Bosch, Fabrizio Esposito, (unknown), Dario Dornbierer, Robin von Rotz, Philipp Stäempfli, Boris B. Quednow, Erich Seifritz	18
14	Neural underpinnings of prosexual effects induced by gamma-hydroxybutyrate in healthy male humans 2017 ·European Neuropsychopharmacology ·Oliver G. Bosch, (unknown), (unknown), Katrin H. Preller, Robin von Rotz, Marcus Herdener, Rainer Kraehenmann, Philipp Stäempfli, Milan Scheidegger, Tim Klucken, Erich Seifritz, Boris B. Quednow	16
15	Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state 2017 ·Biological Psychology ·Avinash Ramyead, Michael Kometer, Erich Studerus, (unknown), Robin von Rotz, Anita Riecher‐Rössler	1
16	Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone 2015 ·Psychoneuroendocrinology ·Oliver G. Bosch, Christoph Eisenegger, Jürg Gertsch, Robin von Rotz, Dario Dornbierer, M. Salomé Gachet, Markus Heinrichs, Thomas C. Wetter, Erich Seifritz, Boris B. Quednow	30
17	Pharmacokinetics and pharmacodynamics of γ‐hydroxybutyrate in healthy subjects 2015 ·British Journal of Clinical Pharmacology ·Matthias E. Liechti, Boris B. Quednow, Evangelia Liakoni, Dario Dornbierer, Robin von Rotz, M. Salomé Gachet, Jürg Gertsch, Erich Seifritz, Oliver G. Bosch	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact